Should durvalumab consolidation still be offered to Stage III NSCLC patients with PD-L1< 1%?  

Do the results of the unplanned subset analysis of the PACIFIC trial showing no OS benefit in this population lean you away from consolidation?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at Northwest Georgia Oncology Centers
Thank you for the detailed answers. What if you ha...
Medical Oncologist at Wenatchee Valley Med Center
@Yuesheng Qu, I have a patient currently who is in...
Medical Oncologist at Ohio State University College of Medicine
@Thomas B. Tucker, I am offering chemo-IO as first...
Sign in or Register to read more